Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen to Provide Intradigm with siRNA in Drug Discovery Collaboration

NEW YORK, July 8 - Qiagen and Intradigm will collaborate in siRNA drug discovery research & development projects, the companies said today.


Under the agreement, Qiagen will manufacture the siRNA (short interfering RNA), which it will provide to Intradigm for research in oncology, arthritis, and SARS.


For the SARS coronavirus project, Intradigm will design at least 48 sets of siRNA oligos for delivery through the airways, as a potential treatment for the pulmonary infection caused by the virus. The company said it will conduct this project with collaborators at the National Institute of Allergy and Infectious Diseases, as well as ones in Hong Kong and Guangzhou,China


The companies did not disclose the financial terms of the agreement.


Qiagen, of Venlo, the Netherlands, manufactures siRNA for gene silencing using its TOM-Amidite chemistry. The company is one of four companies licensed to supply siRNA under a group of patent applications held by MIT, the Whitehead Institute, the Max Planck Institute, and the University of Massachusetts Medical School.


Intradigm, of Rockville, Md., has developed methods of delivering siRNA in animals, and has conducted studies to validate particular siRNA agents for cancer and viral infection.


SiRNA consists of a short double-stranded sequence of RNA that is delivered into a cell, which triggers the destruction of the mRNA from a target gene.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.